Table 1.
Summary of the drugs discussed, which include monotherapy and combination-therapy. Their previous indications are specified where appropriate, along with their postulated roles in SARS-CoV-2.
| Drug | Trade Name | Previous Indication | Postulated role/target in SARS-CoV-2 |
|---|---|---|---|
| Chloroquine | Aralen | Malaria, Rheumatoid arthritis | Inhibit viral entry |
| Hydroxychloroquine | Plaquenil | Malaria, Rheumatoid arthritis | Inhibit viral entry |
| Ivermectin | Stromectol | Antiparasitic | Inhibit nuclear import via IMPα/β |
| Lopinavir-Ritonavir | Kaletra | HIV-1 Mpro | SARS-CoV-2 Mpro |
| Remdesivir | Veklury | EBOV RdRp | SARS-CoV-2 RdRp |
| Dexamethasone | Decadron | Immunomodulatory | Management of pro-inflammatory cytokines |
| Baricitinib | Olumiant | Rheumatoid arthritis, Janus kinase inhibitor | Management of pro-inflammatory cytokines |
| Molnupiravir | Lagevrio | – | SARS-CoV-2 RdRp |
| Nirmatrelvir-Ritonavir | Paxlovid | – | SARS-CoV-2 Mpro |